Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 5, 2007

SymBio Obtains Rights to Leukemia Drug Candidate

  • SymBio Pharmaceuticals obtained rights to a drug that’s touted to have therapeutic potential to treat Gleevec-resistant chronic myeloid leukemia and mast cell leukemia.

    PEG-ZnPP was developed by Hiroshi Maeda and fellow researchers at Sojo University. According to Maeda, PEG-ZnPP exhibits an inhibitory antitumor effect on heme oxygenase activity, leading to an increase in the production of toxic oxidants and eventual cancer cell death.

    This exclusive global license adds a third clinical candidation to SymBio’s pipeline.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »